Very Early Versus Delayed Etanercept in Patients With RA
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The main aim of the study is to determine whether TNFi instituted as first-line therapy in
early RA confers better outcomes (clinical, structural and immunological) compared to delayed
TNFi start; implying particular dominance of TNF in early disease, a changing role of TNF
with disease duration and hence, confirmation of a biological window of opportunity.